| ABSTRACT Objective: To evaluate the safety and efficiency of bendipine for coronary heart disease angina pectoris, in order to provide evidence based reference for clinical use. Methods:CNKI, CDDBFT, WanFang Data, VIP, the Cochrane Library, Medline (EBSCO) and PubMed were electronically searched to collect randomized controlled trials (RCTs) of bendipine for coronary heart disease angina pectoris from inception to October, 2018. Two researchers independently screened literature, extracted data and assessed the risk of bias of included studies, then, Meta analysis was performed by RevMan 5.3 software. Results: A total of 12 RCTs involving 1 460 angina pectoris patients were included. The results of Meta analysis showed that: compared with routine treatment or routine treatment combined with calcium channel blocker, benitepine treatment group could significantly improve the treatment efficiency of patients with angina pectoris (OR=2.56, 95%CI 1.93 to 3.40, P＜0.000 01), prevent ECG S T segment reduced value (MD=-0.34, 95%CI -0.50 to -0.19, P＜0.000 1), reduce diastolic pressure declined after treatment (MD=3.78, 95%CI 0.60 to 6.95, P=0.02). There was no statistically significant difference in reduce systolic pressure declined after treatment between two groups (MD=3.78, 95%CI -0.75 to 8.30, P＞0.05). The incidence of adverse reaction in benitepine treatment group was lower than control group (OR=0.52, 95%CI 0.32 to 0.83, P=0.006). The benitepine treatment group could delayed heart rate increasing (MD=-6.19, 95%CI -8.65 to -3.72, P＜0.000 01). Conclusion:Bendipine demonstrated curative effect on coronary heart disease angina pectoris, and no obvious side effects. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusion. |
